Photo credit: www.foxnews.com
An outbreak of a highly contagious virus, known as human metapneumovirus (HMPV), has raised alarms among health officials in China, particularly as cases are rising sharply in the northern regions. The virus appears to be affecting children aged 14 and under more significantly.
Although HMPV may not be as familiar as other viruses like influenza, it is not a new threat; it was identified in 2001 and belongs to the same viral family as respiratory syncytial virus (RSV), as reported by the U.S. Centers for Disease Control and Prevention (CDC).
Pandemic Concerns
Video footage circulating on social media has shown hospitals in China struggling with high patient volumes, which has prompted discussions about the potential for a pandemic. In response, the Chinese Foreign Ministry has characterized the uptick in cases as a typical seasonal occurrence, stating, “Respiratory infections tend to peak during the winter season,” and emphasizing that the current diseases seem to be less severe and spread on a smaller scale than in previous years.
The CDC is actively monitoring HMPV through its National Respiratory and Enteric Virus Surveillance System (NREVSS). A representative from the CDC remarked that while they are aware of the increased cases in China, there is currently no cause for concern regarding HMPV’s impacts in the U.S., although some transmission is expected annually during the winter respiratory season.
Dr. Marc Siegel, a clinical professor of medicine at NYU Langone Health, noted that while HMPV generally causes mild symptoms, it has the potential to lead to pneumonia in certain individuals. He stressed that while there is no immediate threat of HMPV evolving into a pandemic, there are uncertainties regarding the complete picture due to information flow from China.
Dr. Jacob Glanville, the CEO of Centivax, highlighted that most individuals encounter HMPV by the time they reach five years of age, noting its unique risk to young children but downplaying its broader pandemic potential.
Symptoms and Transmission
HMPV can infect anyone; however, young children, older adults, and those with compromised immune systems are deemed to be at higher risk. The symptoms associated with HMPV are comparable to common cold symptoms, including fever, nasal congestion, and shortness of breath. In severe cases, it may escalate to bronchitis or pneumonia.
The CDC indicates that symptoms typically manifest three to six days following exposure. HMPV transmits predominantly through respiratory droplets from coughing and sneezing, as well as through contact with contaminated surfaces.
Notably, as a seasonal virus, HMPV is most active in the U.S. from winter to spring, coinciding with other respiratory viruses like influenza and COVID-19. Experts suggest it is reasonably low risk in the U.S., with many individuals likely having been exposed at least once during childhood.
Treatment and Preventive Measures
Diagnosis of HMPV can be accomplished through specific tests designed to detect the virus. Currently, the CDC does not endorse a specific treatment for HMPV, which means management typically focuses on symptomatic relief. This may include rest, hydration, non-steroidal anti-inflammatory drugs (NSAIDs), and in some instances, the use of inhalers and steroids. Importantly, while a vaccine is available for RSV, one for HMPV has not yet been approved.
Preventive strategies recommended by the CDC encompass frequent handwashing, avoiding close contact with sick individuals, and covering one’s mouth and nose when coughing or sneezing. Individuals are also urged to stay home if they exhibit symptoms and to sanitize frequently-touched surfaces.
Amid larger outbreaks of respiratory illnesses, including COVID-19 and influenza, experts advise that ensuring vaccinations are up to date is crucial. Rapid tests available over the counter can simultaneously diagnose flu and COVID-19, assisting in managing winter respiratory virus season effectively.
Source
www.foxnews.com